Western blot analysis of extracts from 293T cells, untreated (-) or treated with INK128 (100 nM, 1 hr; +), using Phospho-p70 S6 Kinase (Thr389) (D5U1O) Rabbit mAb #97596 (upper), or p70 S6 Kinase (49D7) Rabbit mAb #2708 (lower).
Chemical structure of INK128.
INK128 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.07 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||309.3 g/mol|
|Solubility||Soluble in DMSO at 25 mg/ml.|
INK128, also known as MLN0128, is a second-generation active-site mTOR inhibitor (asTORi). Treating cells with INK128 leads to the dephosphorylation of mTOR downstream targets including p70 S6 kinase and 4E-BP1 (1,2). Research has proven that INK128 is an effective mTOR inhibitor because it targets both the mTORC1 and mTORC2 complexes at a high potency (Ki = 1.4nM) (1). Studies have shown that INK128 has anti-leukemic effects and can induce apoptosis at higher concentrations (3).